Midlife homocysteine and late-life dementia in women. A prospective population study

Neurobiology of Aging

Volumn 32, Issue 3, 2011, Pages 380-386

  Zylberstein, Dimitri E ^a   Lissner, Lauren ^a   Björkelund, Cecilia ^a   Mehlig, Kirsten ^a   Thelle, Dag S ^a,b   Gustafson, Deborah ^c   Östling, Svante ^c   Waern, Margda ^c   Guo, Xinxin ^c   Skoog, Ingmar ^c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Alzheimer Dementia; Homocysteine; Prospective study; Women

Indexed keywords

HOMOCYSTEINE;

ADULT; ALZHEIMER DISEASE; ARTICLE; BLOOD ANALYSIS; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DEMENTIA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SWEDEN;

ADULT; AGING; COMMUNITY HEALTH PLANNING; CONFIDENCE INTERVALS; DEMENTIA; FEMALE; HOMOCYSTEINE; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; NEUROLOGIC EXAMINATION; PROPORTIONAL HAZARDS MODELS; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 79952899000     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2009.02.024     Document Type: Article

References (47)

1. APA Diagnostic and Statistical Manual of Mental Disorders 1987, (revised (DSM-III-R)). 3rd ed.
2. åsberg M., Montgomery S.A., Perris C., Schalling D., Sedvall G. A comprehensive psychopathological rating scale. Acta Psychiatr. Scand. 1978, (Suppl. (271)):5-27.
3. Bengtsson C., Blohme G., Hallberg L., Hällström T., Isaksson B., Korsan-Bengtsen K., Rybo G., Tibblin E., Tibblin G., Westerberg H. The study of women in Gothenburg 1968-1969-a population study. General design, purpose and sampling results. Acta Med. Scand. 1973, 193(4.):311-318.
4. Björkegren K., Svärdsudd K. A population-based intervention study on elevated serum levels of methylmalonic acid and total homocysteine in elderly people: results after 36 months of follow-up. J. Intern. Med. 2004, 256(5):446-452.
5. Blasko I., Jellinger K., Kemmler G., Krampla W., Jungwirth S., Wichart I., Tragl K.H., Fischer P. Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine. Neurobiol. Aging 2008, 29(1):1-11.
6. Boldyrev A.A., Johnson P. Homocysteine and its derivatives as possible modulators of neuronal and non-neuronal cell glutamate receptors in Alzheimer's disease. J. Alzheimers Dis. 2007, 11(2):219-228.
7. Bonaa K.H., Njolstad I., Ueland P.M., Schirmer H., Tverdal A., Steigen T., Wang H., Nordrehaug J.E., Arnesen E., Rasmussen K. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N. Engl. J. Med. 2006, 354(15):1578-1588.
8. Campbell A.K., Jagust W.J., Mungas D.M., Miller J.W., Green R., Haan M.N., Allen L.H. Low erythrocyte folate, but not plasma vitamin B-12 or homocysteine, is associated with dementia in elderly Latinos. J. Nutr. Health Aging 2005, 9(1):39-43.
9. Dankner R., Chetrit A., Lubin F., Sela B.A. Life-style habits and homocysteine levels in an elderly population. Aging Clin. Exp. Res. 2004, 16(6):437-442.
10. Darvesh S., Walsh R., Martin E. Homocysteine thiolactone and human cholinesterases. Cell Mol. Neurobiol. 2007, 27(1):33-48.
11. Ebbing M., Bleie O., Ueland P.M., Nordrehaug J.E., Nilsen D.W., Vollset S.E., Refsum H., Pedersen E.K., Nygard O. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA 2008, 300(7):795-804.
12. Ferri C.P., Prince M., Brayne C., Brodaty H., Fratiglioni L., Ganguli M., Hall K., Hasegawa K., Hendrie H., Huang Y., Jorm A., Mathers C., Menezes P.R., Rimmer E., Scazufca M. Global prevalence of dementia: a Delphi consensus study. Lancet 2005, 366(9503):2112-2117.
13. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975, 12(3):189-198.
14. Fratiglioni L., Launer L.J., Andersen K., Breteler M.M., Copeland J.R., Dartigues J.F., Lobo A., Martinez-Lage J., Soininen H., Hofman A. Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000, 54(11 Suppl. 5). pp. S10-S5.
15. Fuso A., Seminara L., Cavallaro R.A., D'Anselmi F., Scarpa S. S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. Mol. Cell Neurosci. 2005, 28(1):195-204.
16. Gottfries C.G., Brane G., Gullberg B., Steen G. A new rating scale for dementia syndromes. Arch. Gerontol. Geriatr. 1982, 1(4):311-330.
17. Guo X., Waern M., Sjogren K., Lissner L., Bengtsson C., Bjorkelund C., Ostling S., Gustafson D., Skoog I. Midlife respiratory function and incidence of Alzheimer's disease: a 29-year longitudinal study in women. Neurobiol. Aging 2007, 28(3):343-350.
18. Haan M.N., Miller J.W., Aiello A.E., Whitmer R.A., Jagust W.J., Mungas D.M., Allen L.H., Green R. Homocysteine, B vitamins, and the incidence of dementia and cognitive impairment: results from the Sacramento Area Latino Study on Aging. Am. J. Clin. Nutr. 2007, 85(2):511-517.
19. Ho P.I., Collins S.C., Dhitavat S., Ortiz D., Ashline D., Rogers E., Shea T.B. Homocysteine potentiates beta-amyloid neurotoxicity: role of oxidative stress. J. Neurochem. 2001, 78(2):249-253.
20. Hogervorst E., Ribeiro H.M., Molyneux A., Budge M., Smith A.D. Plasma homocysteine levels, cerebrovascular risk factors, and cerebral white matter changes (leukoaraiosis) in patients with Alzheimer disease. Arch. Neurol. 2002, 59(5):787-793.
21. Hughes C.P., Berg L., Danziger W.L., Coben L.A., Martin R.L. A new clinical scale for the staging of dementia. Br. J. Psychiatry 1982, 140:566-572.
22. Humphrey L.L., Fu R., Rogers K., Freeman M., Helfand M. Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Mayo Clin. Proc. 2008, 83(11):1203-1212.
23. Israelsson B., Brattstrom L., Refsum H. Homocysteine in frozen plasma samples. A short cut to establish hyperhomocysteinaemia as a risk factor for arteriosclerosis?. Scand. J. Clin. Lab. Invest. 1993, 53(5):465-469.
24. Jorm A.F., Korten A.E. Assessment of cognitive decline in the elderly by informant interview. Br. J. Psychiatry 1988, 152:209-213.
25. Lissner L., Skoog I., Andersson K., Beckman N., Sundh V., Waern M., Zylberstein D.E., Bengtsson C., Bjorkelund C. Participation bias in longitudinal studies: experience from the Population Study of Women in Gothenburg, Sweden. Scand. J. Prim. Health Care 2003, 21(4):242-247.
26. Lonn E., Yusuf S., Arnold M.J., Sheridan P., Pogue J., Micks M., McQueen M.J., Probstfield J., Fodor G., Held C., Genest J. Homocysteine lowering with folic acid and B vitamins in vascular disease. N. Engl. J. Med. 2006, 354(15):1567-1577.
27. Luchsinger J.A., Tang M.X., Shea S., Miller J., Green R., Mayeux R. Plasma homocysteine levels and risk of Alzheimer disease. Neurology 2004, 62(11):1972-1976.
28. Mashavi M., Hanah R., Boaz M., Gavish D., Matas Z., Fux A., Shargorodsky M. Effect of homocysteine-lowering therapy on arterial elasticity and metabolic parameters in metformin-treated diabetic patients. Atherosclerosis 2008, 199(2):362-367.
29. McCaddon A., Davies G., Hudson P., Tandy S., Cattell H. Total serum homocysteine in senile dementia of Alzheimer type. Int. J. Geriatr. Psychiatry 1998, 13(4):235-239.
30. McMahon J.A., Green T.J., Skeaff C.M., Knight R.G., Mann J.I., Williams S.M. A controlled trial of homocysteine lowering and cognitive performance. N. Engl. J. Med. 2006, 354(26):2764-2772.
31. Mielke M.M., Rosenberg P.B., Tschanz J., Cook L., Corcoran C., Hayden K.M., Norton M., Rabins P.V., Green R.C., Welsh-Bohmer K.A., Breitner J.C., Munger R., Lyketsos C.G. Vascular factors predict rate of progression in Alzheimer disease. Neurology 2007, 69(19):1850-1858.
32. Mondragon-Rodriguez S., Basurto-Islas G., Santa-Maria I., Mena R., Binder L.I., Avila J., Smith M.A., Perry G., Garcia-Sierra F. Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimer's disease. Int. J. Exp. Pathol. 2008, 89(2):81-90.
33. NINCDS-ADRDA Criteria for the clinical diagnosis of Alzheimer's disease. Excerpts from the NINCDS-ADRDA Work Group report. J. Am. Geriatr. Soc. 1985, 33(1):2-3.
34. Ravaglia G., Forti P., Maioli F., Martelli M., Servadei L., Brunetti N., Porcellini E., Licastro F. Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am. J. Clin. Nutr. 2005, 82(3):636-643.
35. Righetti M., Serbelloni P., Milani S., Ferrario G. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Blood Purif. 2006, 24(4):379-386.
36. Roman G.C., Tatemichi T.K., Erkinjuntti T., Cummings J.L., Masdeu J.C., Garcia J.H., Amaducci L., Orgogozo J.M., Brun A., Hofman A., et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993, 43(2):250-260.
37. Rosen W.G., Mohs R.C., Davis K.L. A new rating scale for Alzheimer's disease. Am. J. Psychiatry 1984, 141(11):1356-1364.
38. Sachdev P. Homocysteine, cerebrovascular disease and brain atrophy. J. Neurol. Sci. 2004, 226(1-2):25-29.
39. Seshadri S., Beiser A., Selhub J., Jacques P.F., Rosenberg I.H., D'Agostino R.B., Wilson P.W., Wolf P.A. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N. Engl. J. Med. 2002, 346(7):476-483.
40. Skoog I., Nilsson L., Palmertz B., Andreasson L.A., Svanborg A. A population-based study of dementia in 85-year-olds. N. Engl. J. Med. 1993, 328(3):153-158.
41. Srikanth V.K., Quinn S.J., Donnan G.A., Saling M.M., Thrift A.G. Long-term cognitive transitions, rates of cognitive change, and predictors of incident dementia in a population-based first-ever stroke cohort. Stroke 2006, 37(10):2479-2483.
42. Ueland P.M., Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J. Lab. Clin. Med. 1989, 114(5):473-501.
43. Vicenzini E., Ricciardi M.C., Altieri M., Puccinelli F., Bonaffini N., Di Piero V., Lenzi G.L. Cerebrovascular reactivity in degenerative and vascular dementia: a transcranial Doppler study. Eur. Neurol. 2007, 58(2):84-89.
44. Wang X., Demirtas H., Xu X. Homocysteine, B vitamins, and cardiovascular disease. N. Engl. J. Med. 2006, 355(2):207-209. (author reply 9-11).
45. Zhu L., Fratiglioni L., Guo Z., Basun H., Corder E.H., Winblad B., Viitanen M. Incidence of dementia in relation to stroke and the apolipoprotein E epsilon4 allele in the very old. Findings from a population-based longitudinal study. Stroke 2000, 31(1):53-60.
46. Zylberstein D.E., Bengtsson C., Bjorkelund C., Landaas S., Sundh V., Thelle D., Lissner L. Serum homocysteine in relation to mortality and morbidity from coronary heart disease: a 24-year follow-up of the population study of women in Gothenburg. Circulation 2004, 109(5):601-606.
47. Zylberstein D.E., Skoog I., Bjorkelund C., Guo X., Hulten B., Andreasson L.A., Palmertz B., Thelle D.S., Lissner L. Homocysteine levels and lacunar brain infarcts in elderly women: the prospective population study of women in Gothenburg. J. Am. Geriatr. Soc. 2008, 56(6):1087-1091.